

**Table SI. Pathological characteristics of the study population (N=387)**

Characteristics	Group A 25(OH)D3 < 20 ng/ml n = 155 (39.7%)	Group B 25(OH)D3 ≥ 20 ng/ml n = 232 (59.4%)
Histological subtype, n (%)		
Acral lentiginous melanoma	3 (2)	8 (3.5)
Lentigo maligna melanoma	5 (3.3)	6 (2.6)
Nodular melanomas	31 (20)	30 (13)
Superficial spreading melanoma	88 (58)	137 (39)
Missing	28 (18)	51 (22)
Clark, n (%)		
Level 2 + level 3	65 (42)	85 (37)
Level 4	74 (48)	123 (53)
Level 5 + level 6	16 (10)	23 (10)
Missing	0	1
Breslow, mean (SD)	1.48 (1.00, 2.50)	1.30 (0.90, 2.09)
Ulceration, n (%)		
No presence	119 (78)	184 (83)
Presence	33 (22)	38 (17)
Missing	3	10
Mitosis, n (%)		
No presence	108 (71)	175 (76)
Presence	21 (14)	22 (9.6)
Missing	2	2
Vascular invasion, n (%)		
No presence	126 (82)	190 (84)
Presence	7 (4.6)	4 (1.8)
Missing	22 (14)	38 (16)
Microsatellites, n (%)		
No presence	114 (75)	175 (77)
Presence	3 (2.0)	4 (1.8)
Missing	38 (24.5)	53 (23)
Perineural invasion, n (%)		
No	49 (32)	83 (36)
Yes	1 (0.7)	5 (2.2)
Missing	105 (67.7)	144 (62)
Tumour infiltrating lymphocytes (TILs), n (%)		
No presence	12 (7.8)	17 (7.6)
Presence	107 (69)	160 (71)
Missing	36 (23.2)	55 (23.7)
pTNM staging (8th edition AJCC), n (%)		
IA=T1aN0M0 or T1bN0M0	27 (18)	54 (23)
IB=T1bN0M0 or T2aN0M0	54 (35)	93 (40)
IIA=T2bN0M0 or T3aN0M0	22 (14)	28 (12)
IIB=T3bN0M0 or T4aN0M0	12 (7.8)	16 (6.9)
IIC=T4bN0M0	8 (5.2)	6 (2.6)
III=everything from N 1a–N3c	31 (20)	34 (15)
Missing	1	1

SD: standard deviation; 25(OH)D3: 25-hydroxyvitamin D3.